Data on synthesis, ADME and pharmacological properties and early safety pharmacology evaluation of a series of novel NURR1/NOT agonist potentially useful for the treatment of Parkinson's disease

André Malanda; Pierre-Yves Abécassis; Pascal Barnéoud; Pascale Brunel; Véronique Taupin; Xavier Vigé; Dominique Lesuisse

doi:10.1016/j.dib.2019.104057

Data on synthesis, ADME and pharmacological properties and early safety pharmacology evaluation of a series of novel NURR1/NOT agonist potentially useful for the treatment of Parkinson's disease

Data Brief. 2019 May 27:27:104057. doi: 10.1016/j.dib.2019.104057. eCollection 2019 Dec.

Authors

André Malanda¹, Pierre-Yves Abécassis², Pascal Barnéoud³, Pascale Brunel⁴, Véronique Taupin³, Xavier Vigé⁵, Dominique Lesuisse³

Affiliations

¹ IDD, Sanofi, 1 av Pierre Brossolette, F-91935 Chilly Mazarin, France.
² DSAR, Sanofi, 13 quai Jules Guesde, F-94403 Vitry-sur-Seine, France.
³ Rare and Neurologic Disease Research, Sanofi, 1 av Pierre Brossolette, F-91935 Chilly Mazarin, France.
⁴ Preclinical safety, Sanofi, 3, digue d' Alfortville, F- 94140 Alfortville, France.
⁵ Translational Science, Sanofi, 1 av Pierre Brossolette, F-91935, Chilly Mazarin, France.

Abstract

This article describes the chemical synthesis, ADME and pharmacological properties and early safety pharmacology evaluation of a series of novel Nurr1/NOT agonist. It is meant as a support to an article recently published in Bioorganic and Medicinal chemistry Letters and entitled "Development of a novel NURR1/NOT agonist from hit to lead and candidate for the potential treatment of Parkinson's disease" [1] and presenting the discovery, scope and potential of these new ligands of these nuclear receptors.